177 related articles for article (PubMed ID: 30051152)
1. Pricing of HPV vaccines in European tender-based settings.
Qendri V; Bogaards JA; Berkhof J
Eur J Health Econ; 2019 Mar; 20(2):271-280. PubMed ID: 30051152
[TBL] [Abstract][Full Text] [Related]
2. Pricing of HPV tests in Italian tender-based settings.
Inturrisi F; Berkhof J
J Med Econ; 2022; 25(1):762-768. PubMed ID: 35616231
[TBL] [Abstract][Full Text] [Related]
3. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment.
Qendri V; Bogaards JA; Baussano I; Lazzarato F; Vänskä S; Berkhof J
Lancet Public Health; 2020 Nov; 5(11):e592-e603. PubMed ID: 33120045
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
Jiang Y; Ni W; Wu J
BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination.
Ng SS; Hutubessy R; Chaiyakunapruk N
Vaccine; 2018 May; 36(19):2529-2544. PubMed ID: 29625764
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
9. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
12. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
[TBL] [Abstract][Full Text] [Related]
13. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
[TBL] [Abstract][Full Text] [Related]
14. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
Van Minh H; My NTT; Jit M
BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
[TBL] [Abstract][Full Text] [Related]
16. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
[TBL] [Abstract][Full Text] [Related]
17. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.
Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K
Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759
[TBL] [Abstract][Full Text] [Related]
18. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
19. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
20. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
